about
Function, regulation and pathological roles of the Gab/DOS docking proteinsActivating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesisImpaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signalingDisruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsGain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndromeOncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signalingWnt4 inhibits cell motility induced by oncogenic RasHow cells switch HIPK2 on and offRaf family kinases: old dogs have learned new tricksMutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hairComplexity in KSR function revealed by Raf inhibitor and KSR structure studiescPLA2 regulates the expression of type I interferons and intracellular immunity to Chlamydia trachomatisRhoA as a mediator of clinically relevant androgen action in prostate cancer cellsMutations in the let-7 binding site - a mechanism of RAS activation in juvenile myelomonocytic leukemia?A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive conditionCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewRegulatory Roles of MAPK Phosphatases in CancerPersonalized treatment for advanced colorectal cancer: KRAS and beyondAre KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Tumors of the neural crest: Common themes in development and cancerNoonan syndromeDevelopmental disease and cancer: biological and clinical overlapsHow cell death shapes cancerThe biology of IQGAP proteins: beyond the cytoskeletonTargeting Cdc42 in cancerNovel allosteric sites on Ras for lead generationOncogenic Kras initiates leukemia in hematopoietic stem cellsThe distinct conformational dynamics of K-Ras and H-Ras A59GAblation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellumCombined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumorsA restricted spectrum of NRAS mutations causes Noonan syndromeSmall-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activityInhibitors that stabilize a closed RAF kinase domain conformation induce dimerizationReactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.Ras protein/cAMP-dependent protein kinase signaling is negatively regulated by a deubiquitinating enzyme, Ubp3, in yeast.The RasGAP proteins Ira2 and neurofibromin are negatively regulated by Gpb1 in yeast and ETEA in humans.
P2860
Q21245511-D313AE29-13C9-424C-9A8C-5CDFA3CE6303Q24294030-DB3BA161-DDD2-480D-B0F3-D8A56A705439Q24294250-B050D4AF-E5FC-49AF-9965-4E639B340690Q24294914-963C9123-7B60-4F4F-B527-799F128960F8Q24296397-E33630B8-10C4-4862-B95A-77A48C33F49FQ24296451-E1A8D4E2-A075-467E-A1E1-6D54A1C446F0Q24299974-C4D808A9-8A68-4F0D-BE74-FCDB7D5A095DQ24310662-CF1CAD5D-86DF-42D2-91A3-27EF78C7563FQ24316181-90F33353-A059-4E88-94E1-C0A94E1DF065Q24336157-6D858385-0D2B-40E5-B7E7-A81E10D71ED8Q24603489-F9419BFA-6459-4FD1-BBF2-23D6429D5C33Q24618182-F3B0862E-1DD5-42C1-ABAD-11AF3355FA9AQ24618899-09ABA829-2E7C-4BEF-81CC-FB91E17472FCQ24620478-FCF32217-BAD6-4539-825C-E94211C71F59Q24655745-D4CA8FDE-7D5E-4A17-B24B-B013B37EE378Q26740067-C9DAF163-23E5-49AD-8676-2D0F74B05E01Q26751025-2DC5DD0A-A792-4F50-9ED2-C3CAE289D922Q26822817-C938F3DD-06DA-4839-8F81-0632799A959AQ26828992-B448E97A-67D1-48D2-9F33-1C44A0A5EF8AQ26864763-A215FC53-204C-49A6-895B-9F3AA0542E0AQ27001641-45C614E9-2BD9-42C2-8373-2D75F5902C21Q27013647-E3F39248-E821-45AC-8E39-802CA2EB3884Q27021441-C5F5FE61-7095-4A22-A531-428601676BD3Q27023065-C3E2F23C-9F15-45FD-89D3-D2FDCB06B550Q27028075-01B0FD68-CB69-47C8-9349-B0BD14A828E5Q27317333-005A990C-96C1-43D8-8E05-55E8DD7E336EQ27331698-676821F3-0642-4513-97FD-5D52B2B96AA4Q27334550-0654D0D3-7302-4C8D-9572-C8805E7F5732Q27335279-932A04ED-2D26-4258-9399-7926AEEC88FDQ27349020-B8F7593C-95AC-4C8A-8615-394CCF44E623Q27658480-FA38B60A-E512-478C-B4CF-09E18C8368C7Q27678097-207FE566-586E-4A31-9A07-3EEFA1EC2BB2Q27678182-E776B673-2D3E-4AB9-BD3E-DB51781204DEQ27851896-55C4F98F-5163-47E1-9013-407C25C9CBBEQ27852093-E9A76ADC-D07A-40CA-BFC8-018732B9990CQ27852958-FE6320F6-F1E7-421A-966C-32B5D5FE9420Q27853104-6499499C-FCE7-4DB6-B09F-CA6FC0E326F5Q27853338-397515A4-0BE2-4B52-BF88-95A766AB2FD8Q27930858-3BA507E0-9708-476C-9B89-E4AC41FFE9B2Q27934997-891EC1B3-C3D9-4CF6-BF3D-B984DE05398C
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Hyperactive Ras in developmental disorders and cancer
@ast
Hyperactive Ras in developmental disorders and cancer
@en
type
label
Hyperactive Ras in developmental disorders and cancer
@ast
Hyperactive Ras in developmental disorders and cancer
@en
prefLabel
Hyperactive Ras in developmental disorders and cancer
@ast
Hyperactive Ras in developmental disorders and cancer
@en
P2093
P2860
P3181
P356
P1476
Hyperactive Ras in developmental disorders and cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/NRC2109
P407
P577
2007-04-01T00:00:00Z
P5875
P6179
1040267703